Replies to post #4829 on Halozyme Therapeutics Inc (HALO)

[maumar]

Okay, so if royalties are at 3.5%, potential is approximately $131M a year, at $4% it is $150M. Also, sales of Rituximab are expected to grow for several years, I believe.

"Including all approved indications, Roche reported total 2015 sales of rituximab in the United States of 3.76 billion CHF."